Artificial intelligence has generated considerable discussion about operational, regulatory, and compliance risks that may translate into D&O underwriting exposure. An August 27, 2026, ruling allowing a securities class action against CVS to proceed highlights a growing source of securities litigation risk arising when AI-enabled business processes materially contribute to financial performance. The Southern District of New York granted in part and denied in part CVS’s motion to dismiss, permitting claims to proceed based on allegations that the company failed to disclose material information regarding the role AI-assisted prior authorization processes allegedly played in generating cost savings and supporting profitability.

The CVS case is noteworthy not only because of the court’s ruling, but also because of how the underlying allegations evolved. The original securities class action complaint focused primarily on alleged forecasting shortcomings, rising Medicare Advantage utilization, and the adequacy of the company’s financial guidance. The amended complaint, however, expanded the fraud theory to center on allegations that CVS failed to disclose the extent to which AI-assisted prior authorization processes contributed to cost savings, profitability, utilization trends, and other key financial metrics.

As discussed below, the plaintiffs’ amended allegations and surviving claims underscore how AI-related business practices can create D&O exposure.

The CVS SCA

The original securities class action complaint, filed on July 12, 2024, was brought on behalf of a putative class of CVS investors and asserted claims for securities fraud under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, as well as Section 20(a) control-person liability claims against certain executives. The complaint focused primarily on allegations that CVS and senior executives misled investors about the Health Care Benefits segment by using forecasts that failed to adequately account for rising medical costs and Medicare Advantage utilization. According to the complaint, these deficiencies caused CVS to overstate profitability and issue misleading guidance regarding the segment’s financial performance, leading investors to purchase securities at artificially inflated prices.

The amended securities complaint, filed on March 4, 2025, asserts claims under Section 10(b) and Rule 10b-5, along with Section 20(a) claims against senior executives. The complaint also substantially broadened the alleged fraud theory, contending that CVS misled investors about the drivers of its Medicare Advantage performance by concealing the extent to which AI-assisted prior authorization processes and related claim denial practices allegedly reduced medical costs, lowered utilization, and supported profitability. The amended complaint also alleges that CVS made misleading statements concerning regulatory compliance, the responsible use of AI, and the adequacy of its financial guidance.

Notably, it was this AI-focused disclosure theory, rather than many of the plaintiffs’ original forecasting and utilization allegations, that ultimately survived the motion to dismiss.

The Ruling

The Southern District rejected several of the plaintiffs’ theories, including allegations that CVS’s use of AI violated Medicare regulations and claims based on the company’s statements regarding its commitment to “responsible AI,” which the court found to be nonactionable corporate puffery. However, the court allowed claims to proceed based on allegations that CVS identified specific drivers of its financial performance while omitting information about the role AI-assisted prior authorization processes allegedly played in generating cost savings and profitability. The court further concluded that plaintiffs had adequately alleged that the omission of information about those processes could have rendered other statements about the company’s financial performance misleading.

Update: Following the court’s August 27, 2026, ruling, CVS filed a Motion for Reconsideration on September 10, 2026, seeking dismissal of the remaining claims. CVS argues that the court overlooked allegations indicating that AI tools were used to auto-approve, rather than deny, prior authorization requests and that these alleged errors undermine the surviving claims.

Discussion

One of the most significant features of the CVS case is the transformation of the plaintiffs’ theory from a traditional forecasting and utilization case into an AI-related disclosure case. The original complaint focused on alleged forecasting failures, rising Medicare Advantage utilization, and misleading guidance. The amended complaint shifted the focus to allegations that CVS failed to disclose the extent to which AI-assisted prior authorization processes contributed to cost savings, lower utilization, and profitability.

That evolution may be significant because it reflects a broader shift in AI-related securities claims. Unlike earlier cases that focused on representations about AI capabilities or strategy, the CVS case centers on whether AI-enabled processes became sufficiently important to a company’s operations and financial results that investors were entitled to understand their role. Increasingly, the question for securities plaintiffs may not be whether a company uses AI, but whether AI materially contributes to the results reported to investors.

The CVS case aligns with a growing wave of 2026 AI-related securities suits discussed on The D&O Diary, including actions against Rackspace and CoreWeave, that focus on the disclosure of AI’s operational and financial consequences rather than alleged misrepresentations about AI capabilities. In each case, the central issue is whether investors received an accurate picture of AI’s impact on business performance. The surviving claims are based on allegations that CVS failed to disclose the contribution AI-assisted prior authorization processes allegedly made to cost savings, utilization trends, and profitability, making the significance of AI-enabled processes, rather than the existence of the technology itself, the key disclosure issue.

CVS arguably goes a step further. Rackspace and CoreWeave focus on disclosures surrounding AI-related strategies and investments, while CVS focuses on whether AI-enabled operational processes became a material contributor to financial results. The CVS case is also notable because the evolution of the allegations appears to have been effective for plaintiffs’ counsel. While the original complaint focused on forecasting failures, utilization trends, and guidance, the amended complaint reframed the case around the alleged contribution of AI-assisted prior authorization processes to CVS’s financial performance.

In allowing the claims to proceed, the court concluded that plaintiffs plausibly alleged that those AI-assisted processes were important enough to CVS’s results that omitting their role could have rendered other statements misleading. As a result, D&O underwriters may increasingly need to ask not only whether a company uses AI, but whether AI is a material driver of reported results and whether investors have been adequately informed of its contribution.